Drugs / Souvenaid
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04147624 | Jun 2021 → Dec 2022 | cognitive disorder | University of Miami | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Souvenaid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04147624 ↗ |
| Modality | Other / unclassified | “Souvenaid is an oral beverage that contains a vitamin mixture (Vitamin A, B1, B2, B3, B5, D) plus three main active ingredients: omega-3 fatty acids, uridine monophosphate, and choline.” NCT04147624 ↗ |
| Route | Oral | “Participants in the treatment group will receive 125 mL of Souvenaid taken by mouth, once daily, for 6 consecutive months.” NCT04147624 ↗ |